Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stock Has Consensus Target Price of $17.67 According to Brokerages

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been given a consensus rating of “Moderate Buy” by the six research firms that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $17.67.

Several equities analysts have recently issued reports on the company. Weiss Ratings upgraded Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Royal Bank Of Canada lifted their target price on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Friday, August 7th. Finally, Wall Street Zen cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th.

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock opened at $15.83 on Monday. The firm has a 50 day simple moving average of $16.01 and a 200-day simple moving average of $15.84. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97. The stock has a market capitalization of $2.11 billion, a PE ratio of 6.91 and a beta of 1.60. Aurinia Pharmaceuticals has a 12-month low of $10.90 and a 12-month high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The business had revenue of $58.57 million for the quarter, compared to analyst estimates of $80.45 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. As a group, equities research analysts expect that Aurinia Pharmaceuticals will post 0.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Allworth Financial LP boosted its holdings in shares of Aurinia Pharmaceuticals by 34.9% in the second quarter. Allworth Financial LP now owns 3,307 shares of the biotechnology company’s stock worth $56,000 after buying an additional 855 shares during the period. First Trust Advisors LP raised its holdings in shares of Aurinia Pharmaceuticals by 15.5% during the first quarter. First Trust Advisors LP now owns 14,065 shares of the biotechnology company’s stock valued at $208,000 after acquiring an additional 1,883 shares during the period. Nykredit A S acquired a new stake in shares of Aurinia Pharmaceuticals during the second quarter valued at approximately $35,000. Global Retirement Partners LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the second quarter worth $41,000. Finally, Strs Ohio boosted its position in shares of Aurinia Pharmaceuticals by 4.6% in the first quarter. Strs Ohio now owns 56,500 shares of the biotechnology company’s stock worth $837,000 after buying an additional 2,500 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Lupkynis was approved by the U.S. Food and Drug Administration in 2021 and subsequently authorized in Canada.